99 related articles for article (PubMed ID: 28269751)
41. Down-regulation of Barx2 predicts poor survival in colorectal cancer.
Mi Y; Zhao S; Zhang W; Zhang D; Weng J; Huang K; Sun H; Tang H; Zhang X; Sun X; Peng Z; Wen Y
Biochem Biophys Res Commun; 2016 Sep; 478(1):67-73. PubMed ID: 27453340
[TBL] [Abstract][Full Text] [Related]
42. Integrin αvβ6 and matrix metalloproteinase 9 correlate with survival in gastric cancer.
Lian PL; Liu Z; Yang GY; Zhao R; Zhang ZY; Chen YG; Zhuang ZN; Xu KS
World J Gastroenterol; 2016 Apr; 22(14):3852-9. PubMed ID: 27076771
[TBL] [Abstract][Full Text] [Related]
43. Overexpression of Reg4, alone or combined with MMP-7 overexpression, is predictive of poor prognosis in colorectal cancer.
Zhu X; Han Y; Yuan C; Tu W; Qiu G; Lu S; Lu H; Peng Z; Zhou C
Oncol Rep; 2015 Jan; 33(1):320-8. PubMed ID: 25338725
[TBL] [Abstract][Full Text] [Related]
44. Overexpression of Cullin1 is associated with poor prognosis of patients with gastric cancer.
Bai J; Zhou Y; Chen G; Zeng J; Ding J; Tan Y; Zhou J; Li G
Hum Pathol; 2011 Mar; 42(3):375-83. PubMed ID: 21190721
[TBL] [Abstract][Full Text] [Related]
45. Prognostic impact of programed cell death-1 (PD-1) and PD-ligand 1 (PD-L1) expression in cancer cells and tumor infiltrating lymphocytes in colorectal cancer.
Li Y; Liang L; Dai W; Cai G; Xu Y; Li X; Li Q; Cai S
Mol Cancer; 2016 Aug; 15(1):55. PubMed ID: 27552968
[TBL] [Abstract][Full Text] [Related]
46. Increased expression of tumor necrosis factor-α is associated with advanced colorectal cancer stages.
Al Obeed OA; Alkhayal KA; Al Sheikh A; Zubaidi AM; Vaali-Mohammed MA; Boushey R; Mckerrow JH; Abdulla MH
World J Gastroenterol; 2014 Dec; 20(48):18390-6. PubMed ID: 25561807
[TBL] [Abstract][Full Text] [Related]
47. Overexpression of LARP1 predicts poor prognosis of colorectal cancer and is expected to be a potential therapeutic target.
Ye L; Lin ST; Mi YS; Liu Y; Ma Y; Sun HM; Peng ZH; Fan JW
Tumour Biol; 2016 Nov; 37(11):14585-14594. PubMed ID: 27614686
[TBL] [Abstract][Full Text] [Related]
48. Matrix metalloproteinase 2 overexpression and prognosis in colorectal cancer: a meta-analysis.
Shi M; Yu B; Gao H; Mu J; Ji C
Mol Biol Rep; 2013 Jan; 40(1):617-23. PubMed ID: 23184003
[TBL] [Abstract][Full Text] [Related]
49. Clinicopathological correlation and prognostic significance of VEGF-A, VEGF-C, VEGFR-2 and VEGFR-3 expression in colorectal cancer.
Martins SF; Garcia EA; Luz MA; Pardal F; Rodrigues M; Filho AL
Cancer Genomics Proteomics; 2013; 10(2):55-67. PubMed ID: 23603341
[TBL] [Abstract][Full Text] [Related]
50. Matrix metalloproteinase-9 activity is associated with poor prognosis in T3-T4 node-negative colorectal cancer.
Cho YB; Lee WY; Song SY; Shin HJ; Yun SH; Chun HK
Hum Pathol; 2007 Nov; 38(11):1603-10. PubMed ID: 17669467
[TBL] [Abstract][Full Text] [Related]
51. Production of an anti-TM4SF5 monoclonal antibody and its application in the detection of TM4SF5 as a possible marker of a poor prognosis in colorectal cancer.
Park BK; Park JY; Kim TH; Kim D; Wu G; Gautam A; Maharjan S; Lee SI; Lee Y; Kwon HJ; Choi KC
Int J Oncol; 2018 Jul; 53(1):275-285. PubMed ID: 29749436
[TBL] [Abstract][Full Text] [Related]
52. Decreased expression of dual specificity phosphatase 22 in colorectal cancer and its potential prognostic relevance for stage IV CRC patients.
Yu D; Li Z; Gan M; Zhang H; Yin X; Tang S; Wan L; Tian Y; Zhang S; Zhu Y; Lai M; Zhang D
Tumour Biol; 2015 Nov; 36(11):8531-5. PubMed ID: 26032091
[TBL] [Abstract][Full Text] [Related]
53. LGR5 and CD133 as prognostic and predictive markers for fluoropyrimidine-based adjuvant chemotherapy in colorectal cancer.
Stanisavljević L; Myklebust MP; Leh S; Dahl O
Acta Oncol; 2016 Dec; 55(12):1425-1433. PubMed ID: 27435662
[TBL] [Abstract][Full Text] [Related]
54. CRC-113 gene expression signature for predicting prognosis in patients with colorectal cancer.
Nguyen MN; Choi TG; Nguyen DT; Kim JH; Jo YH; Shahid M; Akter S; Aryal SN; Yoo JY; Ahn YJ; Cho KM; Lee JS; Choe W; Kang I; Ha J; Kim SS
Oncotarget; 2015 Oct; 6(31):31674-92. PubMed ID: 26397224
[TBL] [Abstract][Full Text] [Related]
55. Matrix metalloproteinase 2 and tissue inhibitor of matrix metalloproteinases 2 in the diagnosis of colorectal adenoma and cancer patients.
Groblewska M; Mroczko B; Gryko M; Kędra B; Szmitkowski M
Folia Histochem Cytobiol; 2010 Dec; 48(4):564-71. PubMed ID: 21478099
[TBL] [Abstract][Full Text] [Related]
56. Circulating Exosomal MicroRNA-21 as a Biomarker in Each Tumor Stage of Colorectal Cancer.
Tsukamoto M; Iinuma H; Yagi T; Matsuda K; Hashiguchi Y
Oncology; 2017; 92(6):360-370. PubMed ID: 28376502
[TBL] [Abstract][Full Text] [Related]
57. Investigation of microRNA-155 as a serum diagnostic and prognostic biomarker for colorectal cancer.
Lv ZC; Fan YS; Chen HB; Zhao DW
Tumour Biol; 2015 Mar; 36(3):1619-25. PubMed ID: 25528214
[TBL] [Abstract][Full Text] [Related]
58. Fibulin-5 inhibits hepatocellular carcinoma cell migration and invasion by down-regulating matrix metalloproteinase-7 expression.
Tu K; Dou C; Zheng X; Li C; Yang W; Yao Y; Liu Q
BMC Cancer; 2014 Dec; 14():938. PubMed ID: 25494879
[TBL] [Abstract][Full Text] [Related]
59. Immunohistochemically detected high expression of matrix metalloproteinase-2 as predictor of poor prognosis in Duke's B colon cancer.
Sundov Z; Tomić S; Vilović K; Kunac N; Kalebić M; Bezić J
Croat Med J; 2008 Oct; 49(5):636-42. PubMed ID: 18925697
[TBL] [Abstract][Full Text] [Related]
60. DCLK1 is up-regulated and associated with metastasis and prognosis in colorectal cancer.
Gao T; Wang M; Xu L; Wen T; Liu J; An G
J Cancer Res Clin Oncol; 2016 Oct; 142(10):2131-40. PubMed ID: 27520310
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
